Sunesis Appoints Homer L. Pearce, Ph.D., and David C. Stump, M.D., to Board of Directors
29 June 2006 - 11:30PM
PR Newswire (US)
SOUTH SAN FRANCISCO, Calif., June 29 /PRNewswire-FirstCall/ --
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that
Homer L. Pearce, Ph.D., and David C. Stump, M.D., have been
appointed to the company's Board of Directors. Dr. Pearce recently
retired from Eli Lilly & Company where he held leadership
positions in cancer drug discovery and development for more than
twenty-five years. Dr. Stump is Executive Vice President, Drug
Development at Human Genome Sciences, where he is responsible for
clinical research, development and regulatory activities. Sunesis
also announced that Russell Hirsch, M.D., Ph.D., of Prospect
Venture Partners has stepped down from the company's Board after
serving for eight years. "Homer and David bring a wealth of
oncology drug development expertise to the Sunesis Board. We are
pleased to welcome them, and I look forward to their valued input
as we continue to advance our portfolio of cancer therapeutics
through the clinic," said James Young, Ph.D., Executive Chairman of
Sunesis. "In addition, we thank Russell for his distinguished
service and many contributions over the past eight years." Dr.
Pearce has been committed to the discovery and development of
cancer therapeutics since joining Eli Lilly & Company in 1979.
At Eli Lilly, he served in a number of capacities including Vice
President, Cancer Research and Clinical Investigation. During his
twenty-five year career, twenty-five investigational drugs entered
clinical trials and two new drugs, Genzar(R) and Alimta(R), were
approved for the treatment of a variety of cancers. Dr. Pearce is
member of the American Association for Cancer Research, the
American Chemical Society and the American Association for the
Advancement of Science. He received a B.S. from Texas A&M
University and his Ph.D. from Harvard University. Dr. Stump joined
Human Genome Sciences in November 1999 as Senior Vice President,
Drug Development and was promoted to his current position in
December 2003. Prior to joining Human Genome Sciences, Dr. Stump
held roles of increasing responsibility at Genentech, Inc., from
1989 to 1999, most recently as Vice President, Clinical Research
and Genentech Fellow. Dr. Stump joined Genentech from the
University of Vermont where he was Associate Professor of Medicine
and Biochemistry. He earned an A.B. from Earlham College and an
M.D. at Indiana University, followed by residency and fellowship
training in internal medicine, hematology, oncology and
biochemistry at the University of Iowa. About Sunesis
Pharmaceuticals Sunesis is a clinical-stage biopharmaceutical
company focused on the discovery, development and commercialization
of novel small molecule therapeutics for oncology and other serious
diseases. Sunesis has built a broad product candidate portfolio
through internal discovery and in-licensing of novel cancer
therapeutics. Sunesis is advancing its product candidates through
in-house research and development efforts and strategic
collaborations with leading pharmaceutical and biopharmaceutical
companies. For further information on Sunesis Pharmaceuticals,
please visit http://www.sunesis.com/. Forward-Looking Statements
This press release may contain forward-looking statements that
involve substantial risks and uncertainties. Sunesis may not
actually achieve the plans, intentions or expectations contained in
such forward-looking statements. Actual results or events could
differ materially from the plans, intentions and expectations
contained in such forward-looking statements. Sunesis does not
assume any obligation to update any such forward-looking
statements. DATASOURCE: Sunesis Pharmaceuticals, Inc. CONTACT:
investors, Eric Bjerkholt, CFO, of Sunesis Pharmaceuticals, Inc.,
+1-650-266-3717; or media, Karen L. Bergman, or Michelle Corral,
both of BCC Partners, +1-650-575-1509, or +1-415-794-8662, for
Sunesis Pharmaceuticals, Inc. Web site: http://www.sunesis.com/
Copyright
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jul 2024 to Aug 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Aug 2023 to Aug 2024
Real-Time news about Sunesis Pharmaceuticals Inc (NASDAQ): 0 recent articles
More Sunesis Pharmaceuticals (MM) News Articles